Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 52

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 52
---
 ▪ Irreversible ▪ Risk of unsuccessful lenticule extraction, requiring patient to switch to PRK ▪ Limited range of correction ▪ Does not correct hyperopia ▪ Less accessible (not as many surgeons perform procedure) ▪ Irreversible ▪ Risk of corneal haze / poor night vision ▪ Longer recovery time ▪ More patient discomfort during recovery ▪ More post - op visits ▪ Irreversible ▪ Limited range of correction ▪ Higher risk of glare, halo and higher order of aberrations ▪ Risk of dry eye ▪ Risk of serious adverse effects, including flap - related complications (e.g., dislodgement, inflammation, etc.) ▪ Potential issues if sized incorrectly ▪ Risk of premature cataract or glaucoma (though this risk is significantly reduced with the ICL’s current CentraFLOW technology) 1 ▪ Currently the most expensive procedure Risks Source: Wells Fargo Research Note, April 21, 2025; Broadwood analysis. 1. Source: Mark Packer, “The EVO ICL for Moderate Myopia: Results from the US FDA Clinical Trial,” Clinical Ophthalmology , 2022 Dec 6:16:3981 - 3991.

CONFIDENTIAL © All rights reserved. Two Seas Capital LP INVESTOR PRESENTATION APPENDIX B: Trading Multiples of Comparable Medical Technology Companies 06

Broadwood Partners, L.P. Trading Multiples of Comparable Medical Technology Companies 75 Source: FactSet. Data as of September 23, 2025. 1. Based on management’s revised projections as disclosed in STAAR proxy statement on Form DEFM14A, filed with the SEC on Septem ber 16, 2025 at 61. Implied Value of STAAR at EV / Revenue Multiple EV / Revenue Multiple CY 2027E CY 2026E CY 2025E CY 2027E CY 2026E CY 2025E Enterprise Value ($M) Company Name $26.83 $26.32 $23.27 3.5x 3.8x 4.1x $42,008 Alcon AG $21.26 $22.72 $21.75 2.7x 3.2x 3.7x $2,775 Alphatec Holdings, Inc. $20.26 $20.89 $19.20 2.5x 2.9x 3